Intuitive Surgical, Inc.

NasdaqGS:ISRG Stock Report

Market Cap: US$183.5b

Intuitive Surgical Valuation

Is ISRG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ISRG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ISRG ($515.55) is trading above our estimate of fair value ($318.77)

Significantly Below Fair Value: ISRG is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ISRG?

Other financial metrics that can be useful for relative valuation.

ISRG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue22.8x
Enterprise Value/EBITDA71.6x
PEG Ratio7.1x

Price to Earnings Ratio vs Peers

How does ISRG's PE Ratio compare to its peers?

The above table shows the PE ratio for ISRG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.7x
SYK Stryker
39.2x11.2%US$141.0b
BSX Boston Scientific
71.1x23.2%US$126.1b
ABT Abbott Laboratories
35.3x11.7%US$204.2b
MDT Medtronic
29.4x11.3%US$115.0b
ISRG Intuitive Surgical
81.9x11.5%US$183.5b

Price-To-Earnings vs Peers: ISRG is expensive based on its Price-To-Earnings Ratio (81.9x) compared to the peer average (43.7x).

Price to Earnings Ratio vs Industry

How does ISRG's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: ISRG is expensive based on its Price-To-Earnings Ratio (81.9x) compared to the US Medical Equipment industry average (35.9x).

Price to Earnings Ratio vs Fair Ratio

What is ISRG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ISRG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio81.9x
Fair PE Ratio40.4x

Price-To-Earnings vs Fair Ratio: ISRG is expensive based on its Price-To-Earnings Ratio (81.9x) compared to the estimated Fair Price-To-Earnings Ratio (40.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ISRG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$515.55
US$529.70
+2.7%
12.0%US$604.00US$265.00n/a26
Oct ’25US$484.76
US$486.45
+0.3%
12.2%US$586.00US$265.00n/a26
Sep ’25US$492.63
US$482.03
-2.2%
12.4%US$586.00US$265.00n/a26
Aug ’25US$450.94
US$469.35
+4.1%
11.0%US$525.00US$265.00n/a25
Jul ’25US$436.24
US$426.49
-2.2%
11.2%US$500.00US$253.00n/a25
Jun ’25US$402.12
US$423.57
+5.3%
11.0%US$500.00US$253.00n/a25
May ’25US$371.70
US$420.59
+13.2%
10.5%US$475.00US$253.00n/a25
Apr ’25US$394.87
US$414.11
+4.9%
10.5%US$475.00US$253.00n/a25
Mar ’25US$397.90
US$408.45
+2.7%
12.1%US$475.00US$230.00n/a25
Feb ’25US$383.83
US$402.75
+4.9%
13.9%US$475.00US$230.00n/a25
Jan ’25US$337.36
US$337.19
-0.05%
13.2%US$400.00US$230.00n/a25
Dec ’24US$315.20
US$326.63
+3.6%
12.7%US$400.00US$230.00n/a25
Nov ’24US$270.46
US$324.90
+20.1%
12.8%US$400.00US$230.00US$506.3424
Oct ’24US$292.29
US$361.91
+23.8%
10.5%US$400.00US$230.00US$484.7623
Sep ’24US$310.41
US$361.91
+16.6%
10.5%US$400.00US$230.00US$492.6323
Aug ’24US$323.95
US$361.91
+11.7%
10.5%US$400.00US$230.00US$450.9423
Jul ’24US$341.94
US$310.48
-9.2%
10.5%US$365.00US$204.00US$436.2421
Jun ’24US$310.54
US$308.19
-0.8%
10.1%US$365.00US$204.00US$402.1221
May ’24US$303.02
US$305.24
+0.7%
9.6%US$350.00US$204.00US$371.7021
Apr ’24US$255.47
US$271.48
+6.3%
11.5%US$325.00US$204.00US$394.8721
Mar ’24US$227.33
US$273.80
+20.4%
12.3%US$325.00US$204.00US$397.9020
Feb ’24US$251.19
US$273.80
+9.0%
12.3%US$325.00US$204.00US$383.8320
Jan ’24US$265.35
US$271.05
+2.1%
14.7%US$325.00US$204.00US$337.3621
Dec ’23US$274.49
US$260.30
-5.2%
13.8%US$325.00US$204.00US$315.2020
Nov ’23US$246.86
US$252.30
+2.2%
12.4%US$325.00US$204.00US$270.4620

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y